Medios AG: BerlinApotheke to become first Medios Apotheke

DGAP-News: Medios AG / Key word(s): Alliance

24.01.2019 / 11:30

The issuer is solely responsible for the content of this announcement.


Corporate News

Medios AG: BerlinApotheke to become first Medios Apotheke

Berlin, 24 January 2019 – The Management Board of Medios AG (‘Medios’), one of the leading Specialty Pharma companies in Germany, and the owner of BerlinApotheke Anike Oleski e. Kfr., Ms. Anike Oleski, have agreed to rename the four BerlinApotheke branches as Medios Apotheke from 1 March 2019. Medios Apotheke remains an independent company with Ms. Oleski as the sole owner.

Manfred Schneider, CEO of Medios AG: ‘BerlinApotheke stands for the highest quality and competence in the field of Specialty Pharma more than almost any other pharmacy. We want to use this partnership to create consistent quality standards that are immediately apparent and beneficial to patients through the Medios brand. The public presence of Medios Apotheke will also help to increase the visibility of Medios as a leading provider of Specialty Pharma solutions. Our aim is to get more partner pharmacies excited about our idea and to further expand the network of independent Medios pharmacies with different areas of competencies and common quality standards in the Specialty Pharma sector.’

As a competence partner for Specialty Pharma solutions, Medios relies on the principle of collaborative intelligence, in other words linking individual players in the Specialty Pharma market to cooperative partners. The goal is to bring together the special competencies of independent pharmacists on a voluntary basis and without company law relationships, thereby ensuring an optimal pharmaceutical care for patients.

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients and GMP-certified provider of patient-specific therapies, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. It is Medios’ aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany’s first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard) and Hamburg-Hannover Stock Exchange.

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Tel.: +49 4060918618
Fax: +49 4060918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This release contains forward-looking statements that are subject to certain risks and uncertainties. Future results may differ considerably from those currently anticipated due to various risk factors and uncertainties, such as changes in business, economic and competitive conditions, currency exchange rate fluctuations, litigation uncertainties or investigations, and availability of financial resources. Medios AG does not assume any responsibility for updating the forward-looking statements contained in this release.


24.01.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 – 800
Fax: +49 30 232 566 – 801
E-mail: ir@medios.ag
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard), Hamburg; Regulated Unofficial Market in Dusseldorf

 
End of News DGAP News Service

show this

EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF PHASE II CLINICAL TRIAL

DGAP-News: Evotec AG / Key word(s): Miscellaneous

24.01.2019 / 07:30

The issuer is solely responsible for the content of this announcement.


  • EVOTEC’S PARTNER, SECOND GENOME, BEGINS A PHASE II CLINICAL TRIAL FOR NASH WITH LICENSED MOLECULE, SGM-1019

Hamburg, Germany, 24 January 2019: Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that it has earned a $ 2 m milestone payment from Second Genome, Inc., a leading microbiome science-based discovery & development company, for the initiation of a Phase II clinical study of SGM-1019, a first-in-class oral therapeutic for the treatment of nonalcoholic steatohepatitis (NASH). The Phase II trial of SGM-1019 has been initiated following the completion of two successful Phase I trials.

Since 2015, Evotec and Second Genome have been collaborating under a discovery and development agreement focused on the identification of novel microbiome assets. As part of the collaboration, Second Genome and Evotec worked together to screen microbiome-mediated targets of interest identified by the Second Genome microbiome discovery platform with Evotec’s technology platform, chemical libraries and other pre-clinical capabilities. The agreement between Evotec and Second Genome triggered an undisclosed upfront payment and Evotec is eligible for clinical and regulatory milestones as well as royalty payments related to commercialisation.

Dr Werner Lanthaler, CEO of Evotec, commented: “We are proud to see the progression of SGM-1019 into Phase II safety and efficacy studies at Second Genome. This advancement highlights Evotec’s ability to discover novel clinical candidates for which we receive milestones and royalties, and further demonstrates the success of Evotec’s partnered drug discovery strategy.”

Dr Karim Dabbagh, President & CEO of Second Genome, added: “The partnership with Evotec (Aptuit), that encompasses pre-clinical and manufacturing activities, allowed us to efficiently translate output from our microbiome discovery platform into tangible drug molecules for clinical development.”

About SGM-1019
SGM-1019 is an oral small molecule inhibitor of the P2X7 receptor, which plays a key role in activating the inflammasome and has been implicated in causing inflammatory diseases such as NASH and inflammatory bowel disease. In numerous pre-clinical NASH models, inhibition of P2X7 has been shown to be protective in animals. In clinical studies in healthy volunteers, up to twice daily dosing for 2 weeks with SGM-1019 was found to be safe and fully inhibited the P2X7 receptor in whole blood.

ABOUT SECOND GENOME
Second Genome is a clinical-stage company focused on discovering and developing therapeutics identified using microbiome science. The company is advancing its lead program, SGM-1019, into a Phase II clinical trial in NASH, plans to file an IND for a second clinical candidate involved in mucosal healing, and has a pipeline of discovery candidates in the area of immuno-oncology. The deep pipeline results from Second Genome’s robust drug discovery platform, which elucidates and interrogates important microbial (microbiome) functions that strongly influence human health and disease as the basis for therapeutic discovery. Central to this platform is the world’s largest, dynamic, curated database and a suite of software, hardware and data science capabilities that allows Second Genome to accurately identify microbial biology in health and disease. For more information, please visit www.secondgenome.com.

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,500 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry’s need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to
www.evotec.com and follow us on Twitter @EvotecAG.

FORWARD LOOKING STATEMENTS
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com


24.01.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Biotest AG: Biotest receives Intratect(R) approval for additional indications in 22 European countries

DGAP-News: Biotest AG / Key word(s): Regulatory Approval

24.01.2019 / 07:00

The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Biotest receives Intratect(R) approval for additional indications in 22 European countries

– Additional fields of use in neurology (CIDP, MMN) and secondary immunodeficiencies (SID)

– 40% of the globally produced immunoglobulins are used in the treatment of these diseases

– Biotest plans to enter new markets

Dreieich, 24 January 2019. Biotest has received the extension of the approved indications of Intratect(R) for the neurological indications chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), as well as an extension in the field of secondary immunodeficiencies (SID).

CIDP is globally the most important neurological indication in immunoglobulin therapy – approximately 25% of the world’s standard immunoglobulins are administered to treat CIDP. To date, Intratect(R) has been used very successfully for the treatment of acute neurological disorders such as Guillian-Barré syndrome (GBS).

Another application field of Intratect(R) are the primary and secondary immunodeficiency diseases (PID, SID). Reasons for the development of SIDs include various cancers, side effects of immunosuppressive drugs or metabolic disorders. At least 15% of the world’s immunoglobulin levels are prescribed in the area of secondary immunodeficiencies. The label extension eliminates previous limitations of Intratect(R) approval.

With the broader range of indications, Biotest plans to enter new markets to enable additional patients to receive immunoglobulin therapy with Intratect(R).

About CIDP
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare acquired disorder of the peripheral nervous system. It manifests as relapsing or chronic progressive proximal and distal muscle weakness and frequent sensory disturbances. It can occur at any age. The prevalence is given as 0.8 to 8.9 cases per 100,000 inhabitants. In people with an average age of about 40-50 years, the disease occurs more frequently. A cure of the CIDP is rather rare. Nowadays high remission and clinical stability can be obtained through high dose immunoglobulin therapy.

About Intratect
Intratect(R) is a polyvalent immunoglobulin G preparation from human blood plasma for intravenous administration (IVIG). The ready-to-use solution is suitable for replacement therapy in primary and secondary antibody deficiency syndrome as well as for immunomodulation in autoimmune diseases such as ITP, GBS, CIDP, MMN and Kawasaki syndrome. Dosage and duration of treatment depend on the indication and the severity of the disease.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition, Biotest develops monoclonal antibodies in certain cancer indications and in systemic lupus erythematodes, an autoimmune disease, which are produced by recombinant technologies. Biotest has more than 1,600 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201
Preference shares: securities’ ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.


24.01.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 – 8 01-0
Fax: 0 61 03 – 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

AEVIS VICTORIA SA: Rosenklinik, ideally located in the canton of St-Gallen, joins Swiss Medical Network

AEVIS VICTORIA SA / Key word(s): Acquisition

23-Jan-2019 / 17:35 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 KR

The issuer is solely responsible for the content of this announcement.


PRESS RELEASE

Rosenklinik, ideally located in the canton of St-Gallen, joins Swiss Medical Network

Located in the centre of Rapperswill, in the canton of St. Gallen, and easily accessible to patients living on both sides of Lake Zurich, Rosenklinik joins Swiss Medical Network. This increases the number of hospitals of the group to 17 and the number of cantons to 12.

Rosenklinik, founded by Dr Marcel Jud and Dr Martin Pfister in 1995, moved to new premises near the Rapperswill train station in 2016. The operations of the clinic will be integrated into Swiss Medical Network as of February 1st, 2019. The continuation of the activities and its development will be in line with the strategic approach initiated by its founders. Rosenklinik is a listed hospital in the canton of St. Gallen with mandates for orthopaedics, surgery, urology and a partial mandate for neurosurgery. The integration of its activities within a group with a broad national base will allow the clinic to reinforce its services. Synergies with the group’s various establishments, especially Privatklinik Bethanien in Zurich and Privatklinik Lindberg in Winterthur, will directly benefit the patients and the physicians active in Rosenklinik and in other group entities.

Swiss Medical Network is acquiring an initial 40% stake in Rosenklinik SA through a capital increase, and will acquire the entire share-capital by the end of 2022 at the latest. As part of this acquisition, Swiss Medical Network will secure and promote jobs and support the clinic’s development in the coming years. With the arrival of new physicians, the development of medical synergies and the reinforcement of its service offering, Rosenklinik plans to double its activity in the medium term. In 2017, the clinic performed 1’132 surgical interventions and realised revenues of approximately CHF 10.3 million.

For more information:
Media Relations Swiss Medical Network: +41 79 635 04 10 or +41 79 607 99 69, media@swissmedical.net
Media Relations Rosenklinik SA: Elmar M. Jud, Chairman, +41 79 792 21 60, elmar.jud@advosg.ch

About Swiss Medical Network
With 17 clinics in all three of the country’s main linguistic regions, Swiss Medical Network is one of Switzerland’s two leading private clinics groups. It employs 3’000 persons and works with more than 2’000 physicians. Its growth strategy is based on the acquisition of clinic facilities and the restructuring of their operations. The main objective is to offer first-class medical and hospital care to Swiss and foreign patients. Swiss Medical Network is renowned for the high quality of its services, the value of its brand, the pleasant working environment and an experienced management team.

About Rosenklinik
Rosenklinik was founded in 1995 by orthopaedic surgeons Dr. Marcel Jud and Dr. Martin Pfister. After the retirement of Dr. Pfister 7 years ago, Dr. Jud became the clinic director and had the opportunity to transform Rosenklinik into a limited company and to realise the relocation to the new building in the centre of Rapperswil.

Rosenklinik is a listed hospital in the canton of St. Gallen since 2012 and is accessible to all patients regardless of their insurance coverage (common, semi-private or private), both for illnesses or accidents. The clinic employs approx. 70 persons, including 12 physicians, and offers high quality services in orthopaedics, surgery, hand surgery and pain therapy. Furthermore, it has a mandate for urology and for a subarea of neurosurgery.


End of ad hoc announcement


show this

Dermapharm continues expansion course

DGAP-News: Dermapharm Holding SE / Key word(s): Miscellaneous

23.01.2019 / 07:30

The issuer is solely responsible for the content of this announcement.


Dermapharm continues expansion course

  • Acquisition of Spanish EUROMED S.A. completed
  • Expansion of own packaging competence for granulates and liquids in portion packs

Grünwald, January 23, 2019 – Dermapharm Holding SE (“Dermapharm”), a leading manufacturer of patent-free branded pharmaceuticals for selected therapeutic areas in Germany with a growing international presence, is continuing its expansion course at the beginning of the year. The acquisition of the Spanish company EUROMED S.A. was completed at the beginning of January 2019. Dermapharm also acquired the German company CFP Packaging GmbH as part of an asset deal. In order to continue its profitable growth course in recent years, Dermapharm is not only developing new products in-house and expanding its international presence, but also acquiring companies that suitably complement its portfolio.

On January 3, 2019, the final closing of the acquisition of EUROMED S.A. took place in Madrid. The purchase agreement already concluded on November 18, 2018, had previously been subject to the approval of the antitrust authorities. EUROMED S.A. is a leading manufacturer of standardized herbal extracts and natural active ingredients for the pharmaceutical, nutraceutical and cosmetic industry. With the acquisition of EUROMED, Dermapharm is expanding its own value chain and strengthening its expertise in the growth market for herbal medicinal products. Dermapharm is also taking a further step in expanding its international presence with its own company in Spain and is considering using EUROMED’s local industry know-how to launch its own products on the Spanish market. In 2019, EUROMED S.A. is expected to generate revenues of EUR 70 million and earnings before interest, taxes, depreciation and amortization (EBITDA) of EUR 20 million.

In addition, Dermapharm took over the assets and 16 expert employees from CFP Packaging GmbH, based in Wiedemar near Leipzig, as of January 1, 2019. With this acquisition, Dermapharm has expanded its production capacity by approx. 40 million sticks p.a. and thus created the conditions to meet the growing demand for its successful food supplements, such as VITA aktiv B12 and silicea DIRECT. For Dermapharm, this is a logical step, as, in addition to the increasing demand in Germany, the growing Chinese market in particular requires an expansion of capacities. The company plans to relocate production and jobs to Dermapharm’s nearby main plant in Brehna over the course of 2019.

Dr. Hans-Georg Feldmeier, CEO of Dermapharm Holding SE: “We want to continue growing profitably with Dermapharm this year too and consistently pursue our growth strategy accordingly. With the two acquisitions, we have once again improved our starting position for 2019 and gotten off to a lively start to the new year. We are looking optimistically to the current fiscal year and intend to drive our corporate development forward with great vigor.”

 

Company profile:

Dermapharm – Pharmaceutical Excellence “Made in Germany”

Dermapharm is a leading manufacturer of patent-free branded pharmaceuticals for selected markets in Germany. Founded in 1991, the company is based in Grünwald near Munich and has its main manufacturing facility in Brehna near Leipzig. The company’s integrated business model comprises in-house development, in-house production and distribution of pharmaceuticals and other healthcare products for specifically targeted markets by a medical and pharmaceutical sales force. Dermapharm holds approximately 950 marketing authorizations (Arzneimittelzulassungen) for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, food supplements or supplemental balanced diets. This assortment makes the company unique. In addition to Germany, the company’s core markets also include Austria and Switzerland. The company plans to further expand its international presence. Dermapharm’s business model also includes a parallel import business, which operates under the “axicorp” brand. Based on revenues, Dermapharm was among the top five parallel import companies in Germany in the first half-year 2018.

With a consistent development strategy and numerous successful product and company acquisitions over the past 25 years, Dermapharm has continuously optimized its business and provided external growth impulses in addition to organic growth. Dermapharm intends to continue this profitable growth course in the future. The company is focusing on three strategic growth drivers: in-house development of new products, increase of its international footprint and further acquisitions. These include the acquisition of the pharmaceuticals manufacturer and distributor Trommsdorff in January 2018, whose portfolio includes the well-known brands Keltican(R) forte and Tromcardin(R) complex.

Contacts

Investor Relations
Britta Hamberger
Phone: +49 (0)89 – 64186-233
Fax: +49 (0)89 – 64186-165
e-mail: ir@dermapharm.com
cometis AG
Claudius Krause
Phone: +49 (0)611 – 205855-28
Fax: +49 (0)611 – 205855-66
e-mail: ir@dermapharm.com


23.01.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Dermapharm Holding SE
Lil-Dagover-Ring 7
82031 Grünwald
Germany
Phone: +49 (0)89 64 86-0
E-mail: ir@dermapharm.de
Internet: ir.dermapharm.de
ISIN: DE000A2GS5D8
WKN: A2GS5D
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Zur Rose Group realised its expansion goals in 2018 and grew by over 20 percent

EQS Group-News: Zur Rose Group AG / Key word(s): Development of Sales

23.01.2019 / 06:50


Press release

Zur Rose Group realised its expansion goals in 2018 and grew by over 20 percent

– Growth targets successfully implemented in 2018

– Increase in revenue of 20.8 percent in local currency terms

– Significant expansion of European market leadership

Amid challenging market conditions, the Zur Rose Group successfully implemented its growth targets in the 2018 financial year. With revenue of CHF 1,207.2 million, it significantly exceeded the billion Swiss franc threshold as expected and posted year-on-year growth of 22.8 percent (20.8 percent in local currency terms). The Group further advanced its acquisition strategy in 2018: With PromoFarma, it acquired the largest Spanish marketplace platform operator, and with apo-rot and medpex the mail-order activities of two major e-commerce pharmacies in the German market. Overall, the Group managed to further strengthen its European market leadership.

Marked increase in market share in Germany to over 30 percent
In Germany, the Zur Rose Group increased revenue in 2018 in local currency terms by 33.8 percent to EUR 581.4 million. In Swiss francs growth stood at 38.9 percent. The online over-the-counter (OTC) business grew significantly by 72.6 percent in local currency terms, while growth in the prescription drugs segment (Rx) stands at 5.0 percent. At the beginning of November 2018, the Group successfully completed the integration of the mail-order activities of apo-rot, Hamburg. Furthermore, the Group acquired the mail-order activities of Germany’s third largest e-commerce pharmacy medpex, based in Ludwigshafen, the takeover of which was successfully completed at the beginning of January 2019. Including medpex, the Zur Rose Group has therefore increased its market share in the drugs mail-order business in the core market of Germany from 18 percent to 31 percent while increasing the active number of customers to over five million.

Continuous sales growth in Switzerland
Notwithstanding state-mandated price reductions, Zur Rose succeeded in increasing its revenue in Switzerland by 5.4 percent to CHF 527.0 million in 2018. The physician business (B2B) was the main stability factor, with sales up 5.5 percent. Zur Rose succeeded in increasing its market share in this segment from 23.6 to 24.7 percent. Sales gained 4.3 percent in the B2C business. In November 2018 Zur Rose opened its third shop-in-shop-pharmacy at Limmatplatz Zurich. The concept enables customers to access products across all channels (omnichannel) and thus combines the benefits of in-store trading with those of online trading.

Continuation of expansion strategy in new markets
In 2018, the Zur Rose Group posted revenue of CHF 8.9 million with PromoFarma, which was consolidated in mid-September 2018. PromoFarma is a springboard for the expansion into new markets, cross-border as well as through the addition of new partners in other countries, with a capital-efficient business model. The initial focus is on France and Italy. At the same time, the Group will use the major technology know-how of PromoFarma to set up an e-health platform and promote the digital transformation of its business.

Management continues to expect sales growth of over 20 percent in local currency for 2018 and break-even on EBITDA level, adjusted for exceptional charges and PromoFarma.

The Zur Rose Group will publish the complete 2018 Annual Report on 21 March 2019 and provide details of its outlook until 2022.

Revenue January to December, in CHF thousands
(preliminary figures)
1.1.-31.12.2018 1.1.-31.12.2017 Change
Zur Rose Group 1,207,199 982,921 22.8%
In local currency     20.8%
Organic     6.3%
Segment Switzerland 526,954 499,750 5.4%
B2B 388,599 368,250 5.5%
B2C 132,673 127,149 4.3%
BlueCare (1) 5,682 4,351 n.a.
Segment Germany 671,336 483,171 38.9%
Rx 302,639 277,492 9.1%
OTC 368,697 205,679 79.3%
International      
PromoFarma(2) 8,909 n.a.
Segment Germany, in EUR thousands 581,421 434,675 33.8%
Rx 262,106 249,640 5.0%
OTC 319,315 185,035 72.6%

 

Revenue October to December, in CHF thousands
(preliminary figures)
1.10.-31.12.2018 1.10.-31.12.2017 Change
Zur Rose Group 317,947 271,294 17.2%
In local currency     18.3%
Organic     0.4%
Segment Switzerland 137,179 136,951 0.2%
B2B 100,834 97,797 3.1%
B2C 34,968 37,541 -6.9%
BlueCare(1) 1,377 1,613 n.a.
Segment Germany 172,931 134,343 28.7%
Rx 73,267 75,648 -3.1%
OTC 99,664 58,695 69.8%
International      
PromoFarma(2) 7,837 n.a.
Segment Germany, in EUR thousands 152,114 115,999 31.1%
Rx 64,534 65,243 -1.1%
OTC 87,580 50,756 72.6%

 

1) consolidated per 5 May 2017
2) consolidated per 14 September 2018

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: ir@zurrose.com, phone: +41 58 810 11 49

Media contact
Lisa Lüthi, Head of Corporate Communications
Email: media@zurrose.com, phone: +41 52 724 08 14

Financial Calendar
21 March 2019 Annual Results 2018
17 April 2019 Q1/2019 Trading Update
23 May 2019 Annual General Meeting
21 August 2019 2019 Half-Year Results
23 October 2019 Q3/2019 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management and actively promotes its positioning as an integrated, cross-service healthcare platform. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry.

The Zur Rose Group is internationally present with strong brands, including Germany,s best-known pharmacy brand DocMorris. The company employs over 1,000 people at various locations and generated a turnover of CHF 1,207 million in the 2018 financial year. The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). The CHF 115 million corporate bond issued in July 2018 is also listed on the SIX Swiss Exchange (securities number 42146044, ISIN CH0421460442, ticker ZRO18). Further information at zurrosegroup.com


End of Corporate News


Language: English
Company: Zur Rose Group AG
Walzmühlestrasse 60
8500 Frauenfeld
Switzerland
Phone: +41 52 724 08 14
Internet: www.zurrosegroup.com
ISIN: CH0042615283
Listed: SIX Swiss Exchange

 
End of News EQS Group News Service

show this

Biofrontera AG: Biofrontera announces preliminary unaudited sales revenue and updates consolidated net income guidance for the full year 2018

Biofrontera AG / Key word(s): Preliminary Results/Change in Forecast

Biofrontera AG: Biofrontera announces preliminary unaudited sales revenue and updates consolidated net income guidance for the full year 2018

22-Jan-2019 / 17:02 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Ad-hoc Release pursuant to Art. 17 MAR

Biofrontera announces preliminary unaudited sales revenue and updates consolidated net income guidance for the full year 2018

Leverkusen, Germany, January 22, 2019 – Biofrontera AG (NASDAQ ticker symbol: BFRA, ISIN: DE0006046113), an international biopharmaceutical company, today announced preliminary unaudited revenue for the full fiscal year 2018 and updates its consolidated net income guidance for 2018.

The preliminary unaudited revenue of Biofrontera group for the period January 1 to December 31, 2018 was between EUR 21.0 and EUR 21.2 million. This represents a revenue growth of approximately 76% compared to the previous year period, with pure product sales increasing by around 98%.

Preliminary unaudited product sales in the US are expected to be approximately EUR 14.9 million, compared to EUR 6.3 million in the same period in 2017 (+136%). 12-month product sales in Europe will be around EUR 6.0 million, compared to EUR 4.3 million in the same period last year (+41%).

Revenue in the fourth quarter will amount to about EUR 6.6 million, compared to EUR 4.7 million in the previous year. The strong revenue growth was largely driven by steadily growing sales in the U.S., our largest market, as well as an increase in sales in the EU due to the approval of Ameluz(R) in combination with daylight photodynamic therapy (PDT).

The company has revised its forecast for the 2018 consolidated net income from EUR -15.0 to EUR -16.0 million to EUR -8.0 to EUR -10.0 million. The adjustment includes a negative impact on net income due to the formation of provisions for litigation costs between EUR 3.0 and EUR 3.5 million. These provisions include the estimated costs for legal disputes with Dusa Pharmaceuticals and the Deutsche Balaton Group until a decision at the next instance.

An improvement results from the deferred tax assets on losses carried forward for Biofrontera Pharma GmbH amounting to EUR 10.0 to EUR 11.0 million to be reported for the first time as of 31 December 2018. The subsidiary has already generated profits in the second half of 2018 due to the increased business volume. It can be assumed that Biofrontera Pharma GmbH will continue to generate positive results in the future and thus, use its tax loss carryforwards.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611

Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290
E-mail: ir@biofrontera.com


22-Jan-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq

 
End of Announcement DGAP News Service

show this

MediClin AG: Preliminary Group EBIT mainly burdened by one-off effects – preliminary Group sales meets forecast

MediClin AG / Key word(s): Annual Results

MediClin AG: Preliminary Group EBIT mainly burdened by one-off effects – preliminary Group sales meets forecast

22-Jan-2019 / 16:42 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Preliminary Group EBIT mainly burdened by one-off effects – preliminary Group sales meets forecast

Offenburg, 22.01.2019 – MEDICLIN Aktiengesellschaft (MEDICLIN) informed today, that the preliminary operative Group EBIT will be between EUR 22 to 23 mill. and the preliminary Group EBIT burdened by one-off effects between EUR 14.5 – 15.5 mill. (previous year: 6.6 mill., adjusted EUR 26.7 mill.). Therefore MEDICLIN will not achieve the guidance for the Group EBIT in the amount of EUR 26 mill. The main reason for the decrease in results are possible additional expenses as well as provisions for personnel and other personnel expenses (one-off effects) in the amount of expected about EUR 7.5 mill.

Regarding sales growth of the Group, this will probably reach 6 %.

The disclosure of the preliminary figures for financial year 2018 will be on 22 February 2019 in the usual scale. The annual report 2018 will be available from 29 March 2019 onwards.

The disclosed figures of this press release are subject to the final preparation of the consolidated financial statements, the final audit and the approval of the annual financial statements by the Supervisory Board.


22-Jan-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: MediClin AG
Okenstraße 27
77652 Offenburg
Germany
Phone: +49 (0)781 488-326
Fax: +49 (0)781 488-184
E-mail: alexandra.muehr@mediclin.de
Internet: www.mediclin.de
ISIN: DE0006595101
WKN: 659510
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this

Abivax SA (ABVX-FR): Getting a brake in inflammation

goetzpartners securities Limited

22-Jan-2019 / 14:58 GMT/BST


Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Published to the market and investors on 22nd January 2019 @ 12.31pm (GMT).

Abivax SA (ABVX-FR): Getting a brake in inflammation
Recommendation: OUTPERFORM
Target Price: EUR28.80 (increased from EUR19.50)
Current Price: EUR10.02 (CoB on 21st January 2019)

KEY TAKEAWAY

With proof-of-concept trials in ulcerative colitis (“UC”) suggesting efficacy on a par Abivax’s ABX464 looks a real alternative to approved therapies. A new class of oral drug releasing a natural inflammatory brake, ABX464 could alleviate the treatment failures and possibly safety issues of existing drugs. This would open a significant opportunity in a > $70bn market. We are optimistic that clinical studies planned for 2019E should confirm the UC results and may suggest efficacy in Crohn’s Disease and rheumatoid arthritis (“RA”). There appears a firm basis for a licensing / development deal expected during 2019E. We reiterate our OUTPERFORM recommendation and increase our target price (“TP”) to EUR28.80 (from EUR19.50 / share).

Anti-inflammatory benefits compare well to current drugs – While one must exercise due caution extrapolating from small early trial results to late stage studies, the impact on healing and clinical outcomes of ABX464 compare well with and could exceed the benefits of marketed products particularly other oral drugs like tofacitinib from Pfizer recently approved for used in steroid refractory patients.

Safe and well tolerated – The UC Phase 2a trial and those in HIV suggest that the drug is safe and well tolerated with no evidence of the infections and other serious issues associated with the anti-TNF antibodies or small molecule anti-inflammatory drugs like tofacitinib. A 12-month extension study with the Phase 2a patients has been approved based on ABX464’s continued safety and efficacy.

Large unmet need in substantial market – Although anti-TNF drugs have transformed inflammatory therapy, 30% – 40% of patients still fail or cease to respond. There is an absolute need for a safe effective orally available alternative.

Still potential in HIV – Although the major focus has shifted to inflammation, ABX464 still has potential in HIV where the drug has already shown potential in not only reducing the latent HIV reservoirs that are left untouched by current therapies, but also possibly the chronic inflammation with which these are associated. A high dose (150mg) 16-week study aims to confirm these effects during 2020E.

Further data and partnering expected – It is hoped that a dose-ranging Phase 2b trial will confirm the benefits of ABX464 in UC with PoC Phase 2a trials planned in Crohn’s and RA all reporting 2020E. A licensing / development partnership is expected by Abivax during 2019E. Under-valued at current levels – Currently funded through Q4/2019E, the company aims to secure long term funding through substantial upfront and development milestones though ABX464 partnering in 2019E. We are optimistic that this will be achieved based on the strength of the UC Phase 2a data. DCF analysis indicates a current valuation of EUR28.80 rising to > EUR50 / share with PoC in Crohn’s and RA. We reiterate our OUTPERFORM recommendation and increase our TP to EUR28.80 (from EUR19.50).

Kind regards,

Chris Redhead | Analyst

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | chris.redhead@goetzpartners.com / healthcareresearch@goetzpartners.com

www.goetzpartnerssecurities.com

goetzpartners securities LinkedIn page

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

goetzpartners securities Limited – Team Members

Equity Research Analysts – Martin Brunninger, Brigitte de Lima, Chris Redhead, Martin Piehlmeier and Kieron Banerjee.

Sales / Marketing – Erland Sternby.

Corporate Finance – Ulrich Kinzel, Wolf Dornbusch and Youchen Xin.

Corporate Access and IR – Tanya Tracey and Bettina Ellinghorst.

Compliance – Paul W. Dunne.

Click here to see our privacy policy.

GPSL has a formal client relationship with Abivax SA.

GPSL publishes and distributes “Investment” Research and “Corporate Sponsored” Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority (“FCA”). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation (“GDPR“) – if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This communication (including any attachments) from goetzpartners securities Limited (“GPSL”) is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this communication in error or are not the intended recipient of this communication, please delete and destroy all copies in your possession, notify the sender that you have received this communication, and note that any review or dissemination of, or the taking of any action in reliance on this communication is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this communication nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this communication has been maintained nor that this communication is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaMetry, AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, ResearchFN, Research Tree, RNS Reach, Sentieo and Thomson Reuters.

Please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=065935af-0285-4a30-9fe8-324dbaaa61c7&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this

STADA Arzneimittel Aktiengesellschaft Announcement of the Results of the Tender Offer

DGAP-News: STADA Arzneimittel AG / Key word(s): Bond

22.01.2019 / 09:00

The issuer is solely responsible for the content of this announcement.


NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES.

January 22, 2019 – STADA Arzneimittel Aktiengesellschaft (the “Offeror“) with its registered office at Stadastraße 2-18, 61118 Bad Vilbel, Federal Republic of Germany, hereby announces the results of its offer to purchase for cash (the “Tender Offer“) any and all of its outstanding 1.750% Notes due 2022, issued on April 8, 2015 in an aggregate principal amount of EUR 300,000,000, ISIN XS1213831362, Common Code 121383136, WKN A14KJP (the “Notes“) from holders of the Notes (“Noteholders“). The Tender Offer was made pursuant to the terms and conditions set out in the tender offer memorandum dated January 8, 2019 (the “Tender Offer Memorandum“).

During the period from January 8, 2019 until January 21, 2019, 3 pm CET (the “First Expiration Date“) Holders validly tendered Notes in an aggregate principal amount of EUR 2,489,000 for repurchase.

The Offeror hereby announces that it will accept all such Notes validly tendered as of the First Expiration Date for repurchase under the terms and conditions set out in the Tender Offer Memorandum. The First Payment Date (as defined in the Tender Offer Memorandum) is expected to be January 25, 2019.

Afterwards, Notes will still be outstanding in an aggregate principal amount of EUR 271,581,000.

The Second Expiration Date (as defined in the Tender Offer Memorandum) is expected to be February 20, 2019, 3 pm CET.

Requests for information in relation to the Tender Offer can be directed to the Tender Agent:

THE TENDER AGENT

Deutsche Bank Aktiengesellschaft
Taunusanlage 12
60325 Frankfurt am Main
Federal Republic of Germany

Attention: Trust and Agency Services
Telephone (UK): +44 20 7547 5000
Telephone (Germany): +49 69 910 35270
Email: xchange.offer@db.com

THE OFFEROR

STADA Arzneimittel Aktiengesellschaft
Stadastraße 2 – 18
61118 Bad Vilbel
Federal Republic of Germany

DISCLAIMER

NOT FOR DISTRIBUTION TO ANY U.S. PERSON OR IN OR INTO OR TO ANY PERSON LOCATED IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS) OR ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA.

The Tender Offer has not been made and will not be made, directly or indirectly, in or into, or by use of the mails of, or by any means or instrumentality of interstate or foreign commerce of, or of any facilities of a national securities exchange of, the United States. This includes, but is not limited to, facsimile transmission, electronic mail, telephone and the internet. The Notes may not be tendered in the Tender Offer by any such use, means, instrumentality or facility from or within the United States or by persons located or resident in the United States. Accordingly, copies of this announcement, the Tender Offer Memorandum and any other documents or materials relating to the Tender Offer are not being, and must not be, directly or indirectly, mailed or otherwise transmitted, distributed or forwarded (including, without limitation, by custodians, nominees or trustees) in or into the United States or to any persons located or resident in the United States. Any purported tender of Notes in the Tender Offer resulting directly or indirectly from a violation of these restrictions will be invalid and any purported tender of Notes made by a person located or resident in the United States, or any agent, fiduciary or other Intermediary acting on a non-discretionary basis for a principal giving instructions from within the United States will be invalid and will not be accepted.

The distribution of the Tender Offer Memorandum in certain jurisdictions may be restricted by law. Persons into whose possession the Tender Offer Memorandum comes are required by the Offeror and the Tender Agent to inform themselves about, and to observe, any such restrictions.

This announcement is neither an offer to purchase nor the solicitation of an offer to sell any of the securities described herein, nor shall there be any offer or sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The Tender Offer was made solely pursuant to the Tender Offer Memorandum dated January 8, 2019.

This announcement must be read in conjunction with the Tender Offer Memorandum. This announcement and the Tender Offer Memorandum contain important information which should be read carefully before any decision is made with respect to the Tender Offer. If any Holder is in any doubt as to the action it should take, it is recommended that such Holder seek its own financial and legal advice, including as to any tax consequences, immediately from its stockbroker, bank manager, solicitor, accountant or other independent financial or legal adviser. Any individual or company whose Notes are held on its behalf by a broker, dealer, bank, custodian, trust company or other nominee or intermediary must contact such entity if it wishes to tender Notes in the Tender Offer. None of the Offeror or the Tender Agent makes any recommendation as to whether Noteholders should participate in the Tender Offer.

Neither the information contained in this announcement nor any other documents or materials relating to the Tender Offer have been approved by, or will be submitted for approval to, the Luxembourg Financial Services Authority (Commission de Surveillance du Secteur Financier) for purposes of a public offering or sale in the Grand Duchy of Luxembourg (“Luxembourg“). Accordingly, the Tender Offer may not be made to the public in Luxembourg, directly or indirectly, and neither the Tender Offer Memorandum, nor any other offering circular, prospectus, form of application, advertisement or other material relating to the Tender Offer may be distributed, or otherwise made available in, from, or published in, Luxembourg except in circumstances which do not constitute an offer of securities to the public, subject to prospectus requirements, in accordance with the Luxembourg Act of July 10, 2005 on prospectuses for securities, as amended, and implementing the Prospectus Directive, as amended.

The Offer is not subject to the German Securities Acquisition and Takeover Act (Wertpapiererwerbs- und Übernahmegesetzes (WpÜG)). The offer document has not been submitted to the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin)) for inspection, review and/or approval. The Offer will also not be subject to notification, registration, approval or permission procedures outside of Germany nor have any such procedures been applied or induced for or been granted. The publication, dispatch, distribution or dissemination of the offer document and other documents related to the Offer outside the Federal Republic of Germany may be subject to legal restrictions. The offer document and other documents related to the Offer may not be dispatched to or disseminated, distributed or published by third parties in countries in which this would be illegal. Depositary Banks may not publish, dispatch, distribute, or disseminate the offer document outside the Federal Republic of Germany unless in compliance with all applicable domestic and foreign statutory provisions. The Offer will be made solely pursuant to the terms and conditions of the Offer as laid out in the offer document.

The information contained in this announcement have not been approved by an authorised person for the purposes of section 21 of the Financial Services and Markets Act 2000. Accordingly, such documents and/or materials are not being distributed to, and must not be passed on to, the general public in the United Kingdom. The communication of such documents and/or materials as a financial promotion is only being made to those persons in the United Kingdom: (i) falling within the definition of investment professionals (as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Financial Promotion Order“)), (ii) falling within Article 43(2) of the Financial Promotion Order, including existing members and creditors of the Company; or (iii) to whom it may otherwise lawfully be communicated (all such persons together being referred to as “Relevant Persons“). Any person in the United Kingdom who is not a Relevant Person should not act or rely on this document or materials or any of their content.

This announcement contains forward-looking statements and information that are necessarily subject to risks, uncertainties, and assumptions. No assurance can be given that the transactions described herein will be consummated or as to the terms of any such transactions. The Offeror assumes no obligation to update or correct the information contained in this announcement.


22.01.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STADA Arzneimittel AG
Stadastraße 2-18
61118 Bad Vilbel
Germany
Phone: +49 (0)6101 603-4689
Fax: +49 (0)6101 603- 215
E-mail: ir@stada.de
Internet: www.stada.de
ISIN: DE0007251803
WKN: 725180
Listed: Regulated Market in Dusseldorf; Regulated Unofficial Market in Hamburg, Munich

 
End of News DGAP News Service

show this